Liver Diseases  >>  capecitabine  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
capecitabine / Generic mfg.
NCT00216437: Dose Escalation Study Combining Oral Capecitabine (Xeloda) and Radiotherapy for Patients With Unresectable Liver or Cholangiocarcinoma

Terminated
1
30
US
Capecitabine (Xeloda)
James A. Haley Veterans Administration Hospital, Hoffmann-La Roche
Cancer of Liver
 
03/07
NCT00604409: Study of Capecitabine in Combination With SIR-Spheres in Patients With Advanced Cancer

Completed
1
34
US
SIRT, selective internal radiation therapy, capecitabine, CAPE, Ro 09-1978/000, Xeloda
Fox Chase Cancer Center, Sirtex Medical
Metastatic Liver Cancer
06/14
01/15

Download Options